Company / Operating Cash Flow per Share
Inmune Bio, Inc. Operating Cash Flow per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$1.50
FY2025
5-year range
-$1.60 / -$0.66
FY2021-FY2025
Trend
-124.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $-1.26 to $-1.50 over the past 2 years.
Based on SEC 10-K filings.
-1.50 in FY2025.
Declined from $-1.26 to $-1.50 over the past 2 years.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 124.4% year-over-year.
- Peak operating cash flow per share was recorded in FY2018.
- Lowest operating cash flow per share in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 49.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.50 | -124.4% |
| FY2024 | -$0.67 | +47.2% |
| FY2023 | -$1.26 | +20.9% |
| FY2022 | -$1.60 | -140.8% |
| FY2021 | -$0.66 | -32.7% |
| FY2020 | -$0.50 | -445.9% |
| FY2018 | -$0.09 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026